Shares in Vectura moved higher after the respiratory inhaler developer announced higher revenues, sharply narrower losses and positive data from a Phase II clinical study of a treatment for Parkinson's disease.Vectura said the results of its study show that the Parkinson's treatment VR040 improves the control of movement in patients with the disease.'This study confirms the potential therapeutic benefit of VR040 to Parkinson's patients, and in three separate studies, that it is a safe, easy to use and non-invasive treatment,' said Vectura chief executive Chris Blackwell.Vectura's revenues in the six months to September 30 grew by 15% from same period the previous year to £26.3m. Pre-tax losses narrowed to £0.2m from £3.3m.